Treatment of cognitive dysfunction in major depressive disorder-a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine

被引:64
|
作者
Pehrson, Alan L. [1 ]
Leiser, Steven C. [2 ]
Gulinello, Maria [3 ]
Dale, Elena [2 ]
Li, Yan [1 ]
Waller, Jessica A. [1 ]
Sanchez, Connie [1 ]
机构
[1] Lundbeck Res USA Inc, External Sourcing & Sci Excellence, Paramus, NJ 07652 USA
[2] Landbeck Res USA Inc, Bioanal & Physiol, Paramus, NJ 07652 USA
[3] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA
关键词
Major depressive disorder; Cognitive function; Vortioxetine; Lu AA21004; Electrophysiology; Receptor occupancy; MEDIAL PREFRONTAL CORTEX; CHRONIC MILD STRESS; ADULT HIPPOCAMPAL NEUROGENESIS; ELDERLY GENERAL-POPULATION; ACUTE TRYPTOPHAN DEPLETION; LU AA21004; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; QUANTITATIVE EEG; TREATMENT INCREASES;
D O I
10.1016/j.ejphar.2014.07.044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although major depressive disorder is primarily considered a mood disorder, depressed patients commonly present with clinically significant cognitive dysfunction that may add to their functional disability. This review paper summarizes the available preclinical data on the effects of antidepressants, including monoamine reuptake inhibitors and the multimodal antidepressant vortioxetine, in behavioral tests of cognition such as cognitive flexibility, attention, and memory, or in potentially cognition-relevant mechanistic assays such as electroencephalography, in vivo microdialysis, in vivo or in vitro electrophysiology, and molecular assays related to neurogenesis or synaptic sprouting. The available data are discussed in context with clinically relevant doses and their relationship to target occupancy levels, in order to evaluate the translational relevance of preclinical doses used during testing. We conclude that there is preclinical evidence suggesting that traditional treatment with monoamine reuptake inhibitors can induce improved cognitive function, for example in cognitive flexibility and memory, and that the multimodal-acting antidepressant vortioxetine may have some advantages by comparison to these treatments. However, the translational value of the reviewed preclinical data can be questioned at times, due to the use of doses outside the therapeutically-relevant range, the lack of data on target engagement or exposure, the tendency to investigate acute rather than long term antidepressant administration, and the trend towards using normal rodents rather than models with translational relevance for depression. Finally, several suggestions are made for advancing this field, including expanded use of target occupancy assessments in preclinical and clinical experiments, and the use of translationally valuable techniques such as electroencephalography. (C) 2014 The Authors. Published by Elsevier B.V.
引用
收藏
页码:19 / 31
页数:13
相关论文
共 39 条
  • [1] Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
    Le, Gia Han
    Wong, Sabrina
    Lu, Andy
    Vasudeva, Shreya
    Gill, Hartej
    Badulescu, Sebastian
    Portelles, Daylen Rodriguez
    Zheng, Yang Jing
    Teopiz, Kayla M.
    Meshkat, Shakila
    Kwan, Angela T. H.
    Ho, Roger
    Rhee, Taeho Greg
    Rosenblat, Joshua D.
    Mansur, Rodrigo B.
    McIntyre, Roger S.
    JOURNAL OF AFFECTIVE DISORDERS, 2025, 368 : 798 - 819
  • [2] Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials
    Huang, Kai-Lin
    Lui, Wan-Chen
    Wang, Ying-Yue
    Hu, Gwo-Chi
    Lui, Chien-Hung
    Lee, Wei-Ying
    Hsu, Chien-Chi
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2014, 48 (07) : 663 - 671
  • [3] Duloxetine:: A dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder
    Kirwin, JL
    Gören, JL
    PHARMACOTHERAPY, 2005, 25 (03): : 396 - 410
  • [4] Desvenlafaxine: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Adults With Major Depressive Disorder
    Perry, Richard
    Cassagnol, Manouchkathe
    CLINICAL THERAPEUTICS, 2009, 31 : 1374 - 1404
  • [5] Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy
    Strawn, Jeffrey R.
    Mills, Jeffrey A.
    Croarkin, Paul E.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2019, 29 (04) : 250 - 255
  • [6] Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents A Systematic Review and Meta-analysis
    Locher, Cosima
    Koechlin, Helen
    Zion, Sean R.
    Werner, Christoph
    Pine, Daniel S.
    Kirsch, Irving
    Kessler, Ronald C.
    Kossowsky, Joe
    JAMA PSYCHIATRY, 2017, 74 (10) : 1011 - 1020
  • [7] Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions
    Papakostas, George I.
    Kornstein, Susan G.
    Clayton, Anita H.
    Soares, Claudio N.
    Hallett, Lindsay A.
    Krishen, Alok
    Tucker, Vivian L.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (04) : 226 - 229
  • [8] The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder
    Clevenger, Steven S.
    Malhotra, Devvrat
    Dang, Jonathan
    Vanle, Brigitte
    IsHak, Waguih William
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2018, 8 (01) : 49 - 58
  • [9] Major depressive disorder with mania precipitated by antidepressant use (SNRI - serotonin and noradrenaline reuptake inhibitors)
    Moodley, S.
    SA PHARMACEUTICAL JOURNAL, 2020, 87 (03) : 53 - 55
  • [10] Role of serotonin transporter and receptor gene polymorphisms in treatment response to selective serotonin reuptake inhibitors in major depressive disorder
    Ramesh, Varsha
    Venkatesan, Vettriselvi
    Ramasamy, Balakrishnan
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2022, 37 (04)